#1 Clinical Trials Search in Europe

TETRODOTOXIN

Tetrodotoxin (TTX) is a potent neurotoxin currently being studied in clinical trials for its potential to treat various pain conditions, particularly chemotherapy-induced neuropathic pain. This powerful compound, administered as a subcutaneous injection, has shown promise in several clinical studies for providing relief to patients suffering from pain related to cancer treatments. Research is evaluating different formulations, dosages, and administration schedules to determine the optimal therapeutic approach while assessing its safety profile. This article explores the current state of tetrodotoxin research based on recent clinical trials, focusing on its potential benefits for patients experiencing chemotherapy-related nerve pain.

Table of Contents

What is Tetrodotoxin (TTX)?

Tetrodotoxin, commonly abbreviated as TTX and also known by the brand name Halneuron, is a powerful neurotoxin that is being studied as a medication for treating certain types of pain[1]. Despite being naturally found in pufferfish and some other marine animals as a toxin, in carefully controlled medical doses, TTX shows promising potential as a pain reliever[3].

Available Formulations

Tetrodotoxin for medical use is being tested in several formulations:

  • Liquid injectable formulation – A solution that typically contains 30 μg/mL of TTX[1]
  • Lyophilized formulation – A freeze-dried powder that needs to be reconstituted before use. It comes as a sterile, nonpyrogenic, white powder in a 5 mL glass vial. When reconstituted with 1.1 mL of sterile water, it delivers 1 mL of fluid containing 30 μg of TTX with a pH of 4.0 to 5.5[3]

Medical Uses

Based on clinical trials, Tetrodotoxin is primarily being investigated for treating:

  • Chemotherapy-induced peripheral neuropathy (CIPN) – A common side effect of many chemotherapy drugs that causes nerve damage, pain, and numbness[2]
  • Chemotherapy-induced neuropathic pain (CINP) – The painful sensation that results from nerve damage caused by chemotherapy agents[3]

Chemotherapy-Induced Neuropathic Pain

Chemotherapy-induced peripheral neuropathy is a major dose-limiting side effect of many chemotherapeutic agents including vincristine, paclitaxel, cisplatin, oxaliplatin, bortezomib, and ixabepilone. This condition commonly affects more than 40% of patients receiving these treatments[2].

When patients experience severe peripheral neuropathy, doctors often need to reduce chemotherapy doses or even stop treatment completely. This can potentially affect how well the cancer responds to treatment and might impact prognosis and survival. This creates an important unmet medical need for effective treatments for chemotherapy-induced neuropathic pain[2].

To be eligible for TTX treatment studies, patients typically must have ongoing moderate to severe neuropathic pain related to a prior course of platinum and/or taxane chemotherapy, with no evidence of active progressive disease[3].

How Tetrodotoxin Works

Tetrodotoxin works by blocking sodium channels in nerve cells. These channels are crucial for the transmission of pain signals throughout the body. By blocking these channels, TTX can interrupt the transmission of pain signals, potentially providing relief from neuropathic pain[2][3].

Unlike some other pain medications, TTX appears to have a prolonged effect that can last for weeks after a short course of treatment. This is particularly beneficial for patients who may not want to take daily medications[3].

Dosage and Administration

In clinical trials, Tetrodotoxin is typically administered as a subcutaneous (under the skin) injection in the thigh or abdomen. Various dosing regimens are being studied, including:

  • 15 μg once or twice daily[1]
  • 30 μg once or twice daily[1][3]
  • 45 μg divided into two injections[4]

The most common treatment protocol in current studies is 30 μg twice daily for 4 consecutive days[3]. This short course of treatment is followed by an extended observation period to assess long-term effects on pain reduction.

Effectiveness

Clinical trials are evaluating the effectiveness of Tetrodotoxin using several measures:

  • Numerical Pain Rating Scale (NPRS) – This is a scale from 0 (no pain) to 10 (extreme pain) that patients use to rate their pain levels. The primary measure of effectiveness in many TTX studies is the change in this score from before treatment to several weeks after treatment[2][3].
  • Response rate – The percentage of patients who experience at least a 30% or 50% reduction in pain[3].
  • Duration of response – How long pain relief lasts after the 4-day treatment course[3].
  • Quality of life measures – Including assessments like the Brief Pain Inventory (BPI), Neuropathic Pain Symptoms Inventory (NPSI), and Profile of Mood States (POMS2)[3].

Studies are measuring pain reduction at multiple time points, including 4, 8, and 12 weeks after treatment, to determine how long the effects of a single treatment cycle may last[3].

Safety and Side Effects

Safety assessments in TTX clinical trials include monitoring for adverse events, tracking use of other medications, laboratory tests, neurological assessments, and vital signs[1].

One specific safety concern being studied is the potential effect of TTX on heart rhythm. A dedicated study has been conducted to evaluate whether TTX affects the QT interval on electrocardiograms (ECGs), which could potentially indicate a risk for abnormal heart rhythms[4].

This cardiovascular study assessed single ascending doses of 15 μg, 30 μg, and 45 μg of TTX compared to placebo and moxifloxacin (a medication known to affect QT intervals, used as a positive control). The study evaluated how TTX plasma concentrations affected QTc intervals and other important ECG parameters[4].

Ongoing Research

Multiple clinical trials are ongoing to further evaluate Tetrodotoxin’s efficacy and safety:

  • Comparison studies of different formulations (liquid vs. lyophilized)[1]
  • Dose-finding studies to determine the optimal dose for pain relief with minimal side effects[2]
  • Large-scale efficacy trials comparing TTX to placebo for chemotherapy-induced neuropathic pain[3]
  • Safety studies examining potential cardiovascular effects[4]

These studies are helping to establish whether Tetrodotoxin will become an approved treatment option for patients suffering from chemotherapy-induced neuropathic pain, addressing an important unmet medical need.

Aspect Details
Drug Name Tetrodotoxin (TTX), also referred to as Halneuron in some trials
Administration Method Subcutaneous (SC) injection in the thigh or abdomen
Formulations Studied Liquid and lyophilized (freeze-dried powder) formulations
Dosage Ranges 15 μg, 30 μg, and 45 μg doses tested
Treatment Schedule Typically administered once or twice daily for 4 consecutive days
Primary Conditions Studied Chemotherapy-induced neuropathic pain (CINP) and chemotherapy-induced peripheral neuropathy (CIPN)
Key Outcome Measures Pain reduction using Numerical Pain Rating Scale (NPRS), percentage of patients achieving 30% or 50% pain reduction, duration of pain relief (up to 12 weeks monitored)
Safety Assessments Monitoring of adverse events, cardiovascular effects (QT interval studies), laboratory tests, neurological assessments, vital signs
Secondary Outcomes Quality of life measures, mood assessment, neuropathic pain symptoms, use of rescue medications
Study Designs Randomized, double-blind, placebo-controlled trials with various parallel group and crossover designs

FAQ

  • What is tetrodotoxin (TTX) and how does it work for pain relief? Tetrodotoxin (TTX) is a potent neurotoxin being studied as a medication for pain relief. It works by blocking nerve signals that transmit pain. In clinical trials, TTX is administered as a subcutaneous injection (under the skin) in the thigh or abdomen. Unlike traditional pain medications, TTX appears to provide extended pain relief with just a short course of treatment, potentially offering relief for several weeks after administration.
  • What types of pain conditions is tetrodotoxin being tested for? Based on the clinical trials data, tetrodotoxin is primarily being tested for chemotherapy-induced neuropathic pain and chemotherapy-induced peripheral neuropathy. These are painful conditions that occur as side effects of cancer treatments, particularly from platinum and/or taxane chemotherapy drugs. These conditions often limit chemotherapy dosing and can significantly impact patients' quality of life.
  • How is tetrodotoxin administered in clinical trials? In clinical trials, tetrodotoxin is administered as a subcutaneous (under the skin) injection, typically in the thigh or abdomen. Different dosing regimens are being tested, ranging from 15 to 45 micrograms. Some trials test once-daily dosing while others use twice-daily administration. The treatment course generally lasts for 4 consecutive days, after which patients are monitored for several weeks to assess long-term pain relief effects.
  • What are the potential benefits of tetrodotoxin compared to other pain medications? A key potential benefit of tetrodotoxin is its long-lasting effect. Clinical trials are measuring pain reduction for up to 12 weeks after just a 4-day treatment course. This contrasts with many conventional pain medications that must be taken continuously. Additionally, researchers are studying whether tetrodotoxin can provide meaningful pain reduction (30% or 50% reduction from baseline) without the ongoing side effects or dependency risks associated with some traditional pain medications.
  • What outcomes are researchers measuring in tetrodotoxin clinical trials? Researchers are measuring several important outcomes in tetrodotoxin trials. The primary focus is pain reduction, typically using a Numerical Pain Rating Scale (NPRS) with scores from 0 (no pain) to 10 (extreme pain). They're tracking how quickly pain relief occurs, how long it lasts, and the percentage of patients achieving significant pain reduction (30% or 50% improvement). Other measurements include quality of life assessments, mood changes, neuropathic pain symptoms, and the need for rescue pain medication. Safety monitoring includes tracking side effects and any cardiovascular effects.

Ongoing Clinical Trials on TETRODOTOXIN

  • Study on the Effects of Tetrodotoxin for Pain Relief in Healthy Volunteers

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

Glossary

  • Tetrodotoxin (TTX): A potent neurotoxin being studied as a medication for pain relief. In clinical trials, it's formulated as an injectable drug administered under the skin to block pain signals. Also referred to as Halneuron in some studies.
  • Chemotherapy-induced peripheral neuropathy (CIPN): A common side effect of many chemotherapy drugs that causes nerve damage resulting in pain, numbness, tingling, and weakness in the hands and feet. It affects over 40% of patients receiving certain chemotherapies.
  • Chemotherapy-induced neuropathic pain (CINP): The pain component of chemotherapy-induced peripheral neuropathy, characterized by burning, shooting, or electric-shock sensations resulting from nerve damage caused by chemotherapy treatments.
  • Subcutaneous (SC) injection: A method of administering medication by injecting it beneath the skin, typically in the thigh or abdomen. This is how tetrodotoxin is administered in clinical trials.
  • Lyophilized formulation: A freeze-dried powder form of a medication that requires reconstitution with sterile water before use. Some tetrodotoxin clinical trials test this form of the drug.
  • Liquid formulation: A ready-to-use liquid form of a medication. Some tetrodotoxin clinical trials compare this form to the lyophilized (freeze-dried) version.
  • Numerical Pain Rating Scale (NPRS): A scale used to measure pain intensity, ranging from 0 (no pain) to 10 (extreme pain). It's the primary tool used in tetrodotoxin trials to assess pain levels before and after treatment.
  • Placebo: An inactive substance (typically saline solution in injection trials) given to some participants as a control to compare with the active treatment. This helps determine if the real medication has true effects beyond psychological expectations.
  • Randomized controlled trial: A study design where participants are randomly assigned to receive either the study drug or a placebo/control treatment, allowing for unbiased comparison of outcomes.
  • Double-blind study: A research design where neither the participants nor the researchers know who is receiving the active treatment versus placebo, reducing the potential for bias in assessing outcomes.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion. PK studies help determine appropriate dosing and timing of medications.
  • QT interval: A measurement on an electrocardiogram (ECG) that represents the time it takes for the heart to contract and recover. Some medications can prolong this interval, potentially causing heart rhythm problems.
  • Patient-reported outcome: Information about how a patient feels or functions that comes directly from the patient without interpretation by healthcare providers or anyone else.
  • Dose-finding study: A clinical trial designed to determine the optimal dose of a medication that provides the desired effect with acceptable side effects.
  • Area Under the Curve (AUC): A measurement used in clinical trials to represent the total pain relief experienced over time, calculated from repeated pain assessments throughout the study period.

References

  1. https://clinicaltrials.gov/study/NCT01527734
  2. https://clinicaltrials.gov/study/NCT01655823
  3. https://clinicaltrials.gov/study/NCT05359133
  4. https://clinicaltrials.gov/study/NCT04083833